LncRNA MEG3 promotes cisplatin sensitivity of cervical cancer cells by regulating the miR-21/PTEN axis
出版年份 2022 全文链接
标题
LncRNA MEG3 promotes cisplatin sensitivity of cervical cancer cells by regulating the miR-21/PTEN axis
作者
关键词
-
出版物
BMC CANCER
Volume 22, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-11-08
DOI
10.1186/s12885-022-10188-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer
- (2021) Mao Li et al. ONCOLOGY REPORTS
- LncRNA MST1P2/miR‐133b axis affects the chemoresistance of bladder cancer to cisplatin‐based therapy via Sirt1/p53 signaling
- (2020) Jia Chen et al. JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
- Locoregional Management After Neoadjuvant Chemotherapy
- (2020) Monica Morrow et al. JOURNAL OF CLINICAL ONCOLOGY
- The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics
- (2020) Diana Bautista-Sánchez et al. Molecular Therapy-Nucleic Acids
- Lnc-PICSAR contributes to cisplatin resistance by miR-485-5p/REV3L axis in cutaneous squamous cell carcinoma
- (2020) Dan Wang et al. Open Life Sciences
- Comparison of the survival outcome of neoadjuvant therapy followed by radical surgery with that of concomitant chemoradiotherapy in patients with stage IB2–IIIB cervical adenocarcinoma
- (2020) Tian Tian et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- FGD5‑AS1 promotes cisplatin resistance of human lung adenocarcinoma cell via the miR‑142‑5p/PD‑L1 axis
- (2020) Feng Zhu et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Adenocarcinoma of the uterine cervix: pathologic features, treatment options, clinical outcome and prognostic variables
- (2019) Angiolo Gadducci et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- MEG3: an Oncogenic Long Non-coding RNA in Different Cancers
- (2019) Arwa Al-Rugeebah et al. PATHOLOGY & ONCOLOGY RESEARCH
- Chemotherapy medication errors
- (2018) Saul N Weingart et al. LANCET ONCOLOGY
- Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells
- (2017) Peiming Zheng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Long non-coding RNA MEG3 contributes to cisplatin-induced apoptosis via inhibition of autophagy in human glioma cells
- (2017) Binbin Ma et al. Molecular Medicine Reports
- LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis
- (2017) Pei Wang et al. OncoTargets and Therapy
- Review of the Cervical Cancer Burden and Population-Based Cervical Cancer Screening in China
- (2015) Jiangli Di et al. Asian Pacific Journal of Cancer Prevention
- MiR-21 promoted proliferation and migration in hepatocellular carcinoma through negative regulation of Navigator-3
- (2015) Zhipeng Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma
- (2015) Jing Liu et al. PLoS One
- Upregulation of the long non-coding rna hotair promotes esophageal squamous cell carcinoma metastasis and poor prognosis
- (2012) Fang-Jun Chen et al. MOLECULAR CARCINOGENESIS
- Triptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expression
- (2012) Hao Li et al. PHARMACEUTICAL BIOLOGY
- Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer
- (2011) Ana C Tahira et al. Molecular Cancer
- microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer
- (2011) C Braconi et al. ONCOGENE
- Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer
- (2011) Bin Bao et al. PLoS One
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started